$Cybin (CYBN.US)$ Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
DazzlerAus Shatavia Eskdrige077 : 我已经关注这个人一段时间了,让我明确一点,他对DTJ的看法并不是长期看涨,他修复了一篇关于选举后崩溃的帖子可能存在的可能性
Mr Trecherous 楼主 DazzlerAus :